This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

HUMALOG® (insulin lispro) 200 Units/mL: Do Not Use in a Pump

HUMALOG® (insulin lispro) 200 units/mL is not indicated for approved use in a continuous subcutaneous insulin infusion pump.

Detailed Information

Do NOT administer IL-200 using an insulin pump, CSII.1 

Administering IL-200 via CSII is not recommended because

  • this may result in overdose and severe hypoglycemia (low blood glucose)

  • IL-200 is only available in a Pen, and

  • IL-200 should not be removed from the Pen.

Enclosed Prescribing Information

HUMALOG® (insulin lispro injection [rDNA origin]), Lilly


1. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


CSII = continuous subcutaneous insulin infusion

IL-200 = Humalog® (insulin lispro injection) 200 units/mL

Pen = KwikPen®

Date of Last Review: December 06, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical